Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Aspen Pharmacare Holdings Limited (APN.JO)
ZAc14,991.00
-233.00 (-1.53%)
ZA JNB Healthcare Drug Manufacturers - Specialty & Generic
Address
Aspen Place
Durban, ZA
Durban, ZA
CEO
Stephen Bradley Saad
Website
aspenpharma.com
IPO
2000-01-04
ISIN ZAE000066692
Also trades on
Johannesburg Stock Exchange · APN.JO (ZAc)
Other OTC · APNHF (USD)
Other OTC · APNHY (USD)
Description
Aspen Pharmacare Holdings Limited is a global pharmaceutical entity that develops, manufactures, and distributes a wide array of specialized and branded medicinal products. The company operates through two primary segments: Commercial Pharmaceuticals and Manufacturing. Its diverse product portfolio encompasses essential anesthetic agents, such as general anesthetics, muscle relaxants, and topical preparations. Aspen also provides a comprehensive suite of thrombosis treatments, including various injectable anticoagulants like low molecular weight heparins, Xa inhibitors, and other heparin derivatives. Beyond these, the firm markets numerous regional consumer, prescription, and over-the-counter brands, such as Circadin for sleep, Foxair for respiratory ailments, Maltofer as an iron supplement, Mybulen for pain management, and Zyloric for gout. Additionally, Aspen produces active pharmaceutical ingredients and finished dose form products for other companies. Established in 1850, the company's headquarters are located in Durban, South Africa.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
ZAc14,991.00
-233.00 (-1.53%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.35
Float Shares
366.58M
Free Float %
82.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +7.41% | +8.57% | +4.13% | +6.89% | +52.39% | +23.93% | +19.50% | -15.65% | -10.10% | -54.92% | +3,518.50% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
14,991.00
DCF (Unlevered)
30,653.08
+104.5%
DCF (Levered)
23,225.98
+54.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
75% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 1 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.05
Grey zone
Piotroski F-Score
5 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-3.0% Q4'25: -19.2% (vs Q4'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-124.6% Q4'25: -36.5% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-6.3% Q4'25: +14.3% (vs Q4'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+3.5% Q4'25: +18.2% (vs Q4'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+1.3% Q4'25: +8.6% (vs Q4'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.1% ★ Q4'25: +0.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×16.71× Q4'25: 2.03× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 4 Rev. Ana. 3 EPS Ana. |
Jun 2027 4 Rev. Ana. 3 EPS Ana. |
Jun 2028 4 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
36.13B
est: 36.07B (+0.2%)
|
35.60B
est: 36.88B (-3.5%)
|
41.20B
est: 41.36B (-0.4%)
|
42.60B
est: 44.15B (-3.5%)
|
38.87B
est: 40.05B (-2.9%)
|
38.65B
est: 38.41B (+0.6%)
|
37.77B
est: 37.48B (+0.8%)
|
38.61B
est: 39.16B (-1.4%)
|
40.71B
est: 39.85B (+2.1%)
|
44.71B
est: 45.33B (-1.4%)
|
43.36B
est: 44.60B (-2.8%)
|
40.59B
36.54B – 44.22B
-9.0% YoY
|
38.12B
36.69B – 40.03B
-6.1% YoY
|
40.49B
37.70B – 43.33B
+6.2% YoY
|
| EBITDA |
9.53B
est: 7.31B (+30.4%)
|
9.40B
est: 7.47B (+25.8%)
|
9.50B
est: 8.38B (+13.4%)
|
9.82B
est: 8.95B (+9.7%)
|
5.54B
est: 8.12B (-31.7%)
|
7.27B
est: 7.78B (-6.6%)
|
8.67B
est: 7.59B (+14.1%)
|
10.61B
est: 7.93B (+33.7%)
|
9.67B
est: 8.08B (+19.7%)
|
9.91B
est: 9.19B (+7.8%)
|
2.16B
est: 9.04B (-76.1%)
|
8.23B
7.40B – 8.96B
-9.0% YoY
|
7.72B
7.44B – 8.11B
-6.1% YoY
|
8.21B
7.64B – 8.78B
+6.2% YoY
|
| EBIT |
8.49B
est: 5.94B (+43.1%)
|
8.10B
est: 6.07B (+33.5%)
|
8.20B
est: 6.81B (+20.5%)
|
8.71B
est: 7.26B (+19.8%)
|
4.37B
est: 6.59B (-33.6%)
|
5.71B
est: 6.32B (-9.6%)
|
7.03B
est: 6.17B (+14.0%)
|
8.90B
est: 6.44B (+38.1%)
|
7.88B
est: 6.56B (+20.1%)
|
7.94B
est: 7.46B (+6.5%)
|
1.53B
est: 7.34B (-79.2%)
|
6.68B
6.01B – 7.28B
-9.0% YoY
|
6.27B
6.04B – 6.59B
-6.1% YoY
|
6.66B
6.20B – 7.13B
+6.2% YoY
|
| Net Income |
5.20B
est: 5.06B (+2.8%)
|
4.30B
est: 5.71B (-24.7%)
|
5.10B
est: 6.36B (-19.8%)
|
6.01B
est: 7.44B (-19.2%)
|
6.46B
est: 6.12B (+5.6%)
|
4.66B
est: 5.93B (-21.3%)
|
4.81B
est: 5.44B (-11.7%)
|
6.49B
est: 6.88B (-5.7%)
|
5.23B
est: 6.54B (-20.0%)
|
4.40B
est: 6.13B (-28.2%)
|
-1.08B
est: 5.57B (-119.5%)
|
3.53B
2.58B – 4.48B
-36.6% YoY
|
5.58B
5.19B – 5.97B
+58.0% YoY
|
5.92B
5.12B – 6.73B
+6.1% YoY
|
| SGA |
8.43B
est: 6.04B (+39.7%)
|
8.60B
est: 6.17B (+39.3%)
|
5.50B
est: 6.92B (-20.5%)
|
5.82B
est: 7.39B (-21.2%)
|
5.17B
est: 6.70B (-22.8%)
|
5.03B
est: 6.43B (-21.7%)
|
4.93B
est: 6.27B (-21.5%)
|
4.40B
est: 6.55B (-32.9%)
|
4.60B
est: 6.67B (-31.0%)
|
10.10B
est: 7.58B (+33.2%)
|
10.99B
est: 7.46B (+47.3%)
|
6.79B
6.11B – 7.40B
-9.0% YoY
|
6.38B
6.14B – 6.70B
-6.1% YoY
|
6.78B
6.31B – 7.25B
+6.2% YoY
|
| EPS |
11.40
est: 11.40 (0.0%)
|
9.45
est: 12.86 (-26.5%)
|
11.17
est: 14.32 (-22.0%)
|
13.17
est: 16.75 (-21.4%)
|
14.16
est: 13.79 (+2.7%)
|
10.64
est: 13.35 (-20.3%)
|
9.66
est: 12.25 (-21.2%)
|
14.32
est: 15.50 (-7.6%)
|
11.77
est: 14.93 (-21.2%)
|
9.91
est: 13.89 (-28.7%)
|
-2.44
est: 12.21 (-120.0%)
|
7.36
5.81 – 10.10
-39.7% YoY
|
12.74
11.69 – 13.45
+73.1% YoY
|
13.97
11.52 – 15.16
+9.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-28 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-27 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-26 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-25 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-19 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-18 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-15 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-14 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-12 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-11 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-15 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
8.26B
OE per share TTM
18.60
Owner's Yield
12.83%
Maintenance CapEx ratio
193.28%
Maint CapEx / Avg PPE
42.3%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 76 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | ALPS Emerging Sector Dividend Dogs ETF EDOG | 2.61% | 748.3K | 0.60% |
| 2 | VictoryShares Emerging Markets Value Momentum ETF UEVM | 0.39% | 950.8K | 0.53% |
| 3 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.35% | 417.3K | 0.42% |
| 4 | VanEck Africa Index ETF AFK | 0.25% | 248.7K | 0.76% |
| 5 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.20% | 704.5K | 0.74% |
| 6 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.20% | 1.20M | 0.55% |
| 7 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.20% | 740.5K | 0.72% |
| 8 | T. Rowe Price Emerging Markets Equity Research ETF TEMR | 0.13% | 31.3K | 0.40% |
| 9 | Avantis Emerging Markets Value ETF AVES | 0.11% | 1.69M | 0.36% |
| 10 | JPMorgan Diversified Return Emerging Markets Equity ETF JPEM | 0.10% | 402.6K | 0.44% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
172.1K
Shares Outstanding
444.02M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Stephen Bradley Saad | Group Chief Executive Officer & Executive Director | 15M | male |
| Sean Capazorio | Group Chief Financial Officer & Executive Director | 12M | male |
| Reginald Haman PGDBA | Group Chief Corporate Officer | 11M | male |
| Lorraine Hill | Group Chief Operations Officer | 11M | female |
| Michael Guy Attridge | Group Chief Advisor | 8M | male |
| Trevor Julian Ziman | Regional Chief Executive Officer of Asia Pacific | — | male |
| Luresha Chetty | Corporate Affairs & Investor Relations Executive | — | female |
| Raeesa Khan | Group Company Secretary & Chief of Staff | — | female |
| Samer Kassem | Chief Executive Officer of Aspen Global Incorporated | — | male |
| Sibongakonke Nkosi | Investor Relations Manager | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for APN.JO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
